• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Understanding the Chains of Risk: Data and Products

Share:

August 20, 2019

Data has a chain of elements just as a product has a chain of materials. Both create value by combining their respective elements to benefit a person or institution. The end value of data is information; a manufactured product’s value tends to be more tangible, such as a pacemaker, antibiotics, or a car.

The information data produces is only as reliable as its elements. Similarly, a product is only as good as the skill with which it is designed and the materials and manufacturing processes used to create it.

Many manufacturers use robots programmed to perform tasks in a repetitive fashion with extreme accuracy. However, if the programming is wrong or a sensor is defective, the end quality of the product is likely to suffer—this is why quality control of the product is so important. For the same reason, we must have quality control of the data combined to enrich the data chain, so we can use the resulting information to make accurate decisions.

Consider the manufacture of a pacemaker, a device with two main parts—a pulse generator and leads. The pulse generator is powered by a battery and commanded by a computer. The computer has software, and in some cases, allows for wireless or wired communications with clinicians. The leads are implanted into the heart muscle, and the electrical current from the pulse generator causes the heart to contract. Information from the pacemaker is then manually or automatically sent to clinicians and reviewed to manage care and ensure optimal performance.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

There is no doubt that pacemakers save lives, but what if the computer contains defective software or the wireless connectivity is not entirely secure? A bad actor could exploit these flaws to harm a patient. This is why end products require all materials (many times from third parties) to be properly designed, manufactured, and tested to a level of quality that delivers repeatable operation. If at any point in the supply chain the assembly of the pacemaker involves defective materials and this is not caught in testing, the end product will be at risk for not performing its job and not deliver on its value proposition.

Figure 1 Supply chain of a pacemaker

Just like the pacemaker, data has a supply chain of elements. When combined, these elements produce information that is valuable for decision-making. For example, a patient medical record contains data elements that, when combined, support healthcare decisions. The medical record starts with personally identifiable information, such as full name, and protected health information such as SSN and medical history. Data, often from third-party devices, is added to the data chain. For example, a healthcare provider may measure blood pressure and other vital signs with non-connected devices. The provider then inputs the data into an Electronic Medical Record (EMR) system, which adds it to the medical record.

Connected devices may also add data to the medical record data chain. For example, new connected devices can integrate the recording of a conversation between a healthcare provider and a patient; the device gathers symptoms, additional medical history, and other information, which the EMR system adds to the medical record. These additions to the chain enrich the information, but can also add risk if there are inaccuracies in the update to the EMR. Thus, in many cases, having a review of the data enriching the chain of the medical record is not only a good practice but should be required.

Figure 2 Data chain of a medical record

The integrations and connectivity used to enrich a product and optimize its creation can also sabotage it. The data integrity in the data chain or the material quality in the supply chain can make or break the performance of the end product. Whenever software is an element of a chain, the risk of sabotage can be unknown until years later, due to defects undiscovered until certain software features and functions are used.

Starting with the design process of the product, technology, security, and legal/compliance teams must scrutinize every part of the supply chain. By involving these teams upfront, security can be built into the product to mitigate likely risks. In particular, legal/compliance’s perspective on the ramifications of not moving forward with proposed changes can be very helpful in mitigating expensive and likely risks—helping protect the company’s financial stability. A risk-based assessment process for third parties that are providing parts and materials for the supply chain is also critically important, beginning with knowledge of every item’s source.
It is also important for the data chain to follow these similar concepts:

  1. Include technology, security, and legal/compliance in the design process
  2. Know where the data elements will originate so third-party service providers can be assessed using a risk-based approach
  3. Require your third parties to perform assessments on their third parties to strengthen the data integrity of the data chain
  4. Conduct periodic assessments of third parties

Thus, the elements that make up the data chain for information are very similar to the materials that make up the supply chain for a manufactured product, such as a pacemaker. Many of these elements and materials come from third parties. These third parties can affect the product’s end quality and the reputation of the manufacturer or the steward of the data. In summary, companies must take a risk-based approach to assessments, adapting methods to deal with risks that are continually changing. It is just as important to know the data elements in the data chain that make up a medical record’s information as it is to know the materials and software in the supply chain for a pacemaker.

About Michael

Michael joined ProAssurance as Group Technology Officer in 2013. In January 2014 he became CTO of ProAssurance, a predominantly healthcare liability insurance group committed to treating all fairly. Prior to ProAssurance, Michael spent much of his career in financial services. He was CTO for Sungard Asset management, a technology provider for global financial institutions. Michael’s diverse experience includes Fiserv, EPL, Macromedia, Ernst and Young, Fidelity Investments, and Electronic Data Systems.

Follow Michael on Linkedin

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Walmart Escalates Strategy to Solve Employee HealthcareWalmart Escalates Strategy to Solve Employee Healthcare
  • CBR® Acquires Evercord™ Newborn Stem Cell Business from NateraCBR® Acquires Evercord™ Newborn Stem Cell Business from Natera
  • Healthcare PE Firm Heritage Group Launches $300M Health Tech FundHealthcare PE Firm Heritage Group Launches $300M Health Tech Fund
  • Mirion Technologies Dosimetry Services Division Acquires NRG’s Dosimetry Business in the NetherlandsMirion Technologies Dosimetry Services Division Acquires NRG’s Dosimetry Business in the Netherlands
  • BioAgilytix Closes Acquisition of Australia-Based 360Biolabs®BioAgilytix Closes Acquisition of Australia-Based 360Biolabs®
  • Integrated Passive Device Market is Expected to Witness Growth at a Rate of 9.65% for the Forecast Period of 2022-2029Integrated Passive Device Market is Expected to Witness Growth at a Rate of 9.65% for the Forecast Period of 2022-2029
  • Ginger Acquires Technology Assets of Mental Health App LiveBetterGinger Acquires Technology Assets of Mental Health App LiveBetter
  • COVID-19 Clinical Trials: How AI-Based Chatbots Can Provide Pandemic-Level ExecutionCOVID-19 Clinical Trials: How AI-Based Chatbots Can Provide Pandemic-Level Execution

Trending This Week

  • Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
  • GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies GroupGelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security Market
  • Life Launches AI Clinical Trial Matching Assistant for Cancer
  • 79% of Healthcare Execs Believe Most Drug Diversion Goes Undetected
  • Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine
  • FDA Releases Updated Final Guidance for its Breakthrough Devices Program

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications